AR053446A1 - Compuestos cis-2,4,5-triaril-imidazolinas y su uso como medicamento anti-cancer - Google Patents
Compuestos cis-2,4,5-triaril-imidazolinas y su uso como medicamento anti-cancerInfo
- Publication number
- AR053446A1 AR053446A1 ARP060100970A ARP060100970A AR053446A1 AR 053446 A1 AR053446 A1 AR 053446A1 AR P060100970 A ARP060100970 A AR P060100970A AR P060100970 A ARP060100970 A AR P060100970A AR 053446 A1 AR053446 A1 AR 053446A1
- Authority
- AR
- Argentina
- Prior art keywords
- chosen
- group
- lower alkyl
- lower alkoxy
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos inhiben la interaccion MDM2-p53 y que, como tales, los compuestos tendrán una actividad celular anti- hiperproliferativa. Composicion, uso y proceso. Reivindicacion 1: Un compuesto de formula (1), y las sales y ésteres farmacéuticamente aceptables del mismo; en la que X1 se elige entre el grupo formado por: alcoxi inferior; alcoxi inferior sustituido por trifluorometilo o fluor; X2 y X3 con independencia entre sí se eligen entre el grupo formado por: hidrogeno; halogeno; ciano; alquilo inferior; alcoxi inferior; piperidinilo; -NX4X5; -SO2NX4X5; -C(O) NX4X5; -C(O)X6; -SOX6, -SO2X6; -NC(O)-alcoxi inferior; -C:::C-X7; con la condicion de que X2 y X3 no sean ambos hidrogeno, alquilo inferior ni alcoxi inferior; con la condicion de que cuando X2 o X3 es hidrogeno, el otro no sea alquilo inferior, alcoxi inferior ni halogeno; X2 y X3 pueden tomarse juntos para formar un anillo elegido entre anillos insaturados de 5 a 7 eslabones, y anillos insaturados de 5 a 7 eslabones que contienen por lo menos un heteroátomo elegido entre S, N y O; X4 y X5 con independencia entre sí se eligen entre el grupo formado por: hidrogeno; alquilo inferior; cicloalquilo; alcoxi inferior; alquilo inferior sustituido por alcoxi inferior; -SO2-alquilo inferior; -C(O)-piperazinil-3-ona; X6 se elige entre el grupo formado por: alquilo inferior; morfolina; piperidina; pirrolidina; X7 se elige entre el grupo formado por: hidrogeno; alquilo inferior; trifluorometilo; Y1 e Y2 con independencia entre sí se eligen entre el grupo formado por: halogeno; acetileno; R se elige entre el grupo formado por: alcoxi inferior; piperidinilo sustituido por un heterociclo de cinco o seis eslabones; piperidinilo sustituido por hidroxi, - CH2OH o -C(O)NH2; piperazinilo sustituido por R1; [1,4] diazepanilo sustituido por R1; R1 puede ser uno o dos sustituyentes elegidos entre el grupo formado por: hidrogeno; oxo; alquilo inferior sustituido por R2; -C(O)R3; -SO2-alquilo inferior; -SO2- heterociclilo de cinco eslabones; R2 se elige entre el grupo formado por: -SO2-alquilo inferior; hidroxi; alcoxi inferior; trifluorometilo; -NH-SO2-alquilo inferior; -NH-C(O)-alquilo inferior; -C(O)-alquilo inferior; -ciano; -C(O)R4; R3 se elige entre el grupo formado por: heterociclilo; alquilo inferior; alquenilo inferior; alquilo inferior sustituido por alcoxi inferior o un heterociclilo de cinco o seis eslabones; alcoxi inferior; cicloalquilo; R4 se elige entre el grupo formado por: hidroxi; alcoxi inferior; morfolina; piperidina; pirrolidina; aziridina; 4-acetil-piperazinilo; -NR5R6; R5 y R6 con independencia entre sí se eligen entre el grupo formado por: hidrogeno; alquilo inferior; alquilo inferior sustituido por alcoxi inferior o ciano; alcoxi inferior; y cicloalquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66251605P | 2005-03-16 | 2005-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053446A1 true AR053446A1 (es) | 2007-05-09 |
Family
ID=36572145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100970A AR053446A1 (es) | 2005-03-16 | 2006-03-14 | Compuestos cis-2,4,5-triaril-imidazolinas y su uso como medicamento anti-cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7579368B2 (es) |
| EP (1) | EP1861376A1 (es) |
| JP (1) | JP4955646B2 (es) |
| KR (2) | KR101139263B1 (es) |
| CN (1) | CN101155784A (es) |
| AR (1) | AR053446A1 (es) |
| AU (1) | AU2006224765B2 (es) |
| BR (1) | BRPI0607445A2 (es) |
| CA (1) | CA2599476A1 (es) |
| IL (1) | IL185381A0 (es) |
| MX (1) | MX2007011151A (es) |
| NO (1) | NO20074391L (es) |
| RU (1) | RU2411238C2 (es) |
| TW (1) | TWI314552B (es) |
| WO (1) | WO2006097261A1 (es) |
| ZA (1) | ZA200707653B (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090090383A (ko) | 2006-12-14 | 2009-08-25 | 다이이찌 산쿄 가부시키가이샤 | 이미다조티아졸 유도체 |
| JPWO2009151069A1 (ja) | 2008-06-12 | 2011-11-17 | 第一三共株式会社 | ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体 |
| CN101906085B (zh) * | 2009-06-04 | 2013-12-11 | 天津药物研究院 | 治疗心脑血管疾病的化合物、组合物、制备方法及用途 |
| EP2470502A1 (en) * | 2009-08-26 | 2012-07-04 | Novartis AG | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
| US10159669B2 (en) * | 2010-03-02 | 2018-12-25 | Ian H. Chan | Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US9266860B2 (en) | 2010-09-30 | 2016-02-23 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles |
| FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
| US20120309796A1 (en) | 2011-06-06 | 2012-12-06 | Fariborz Firooznia | Benzocycloheptene acetic acids |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| JP2015531790A (ja) * | 2012-09-19 | 2015-11-05 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | アセチレン架橋したリンカー、及びこれらから製造された金属−有機フレームワーク（ＭＯＦｓ） |
| WO2014082889A1 (en) * | 2012-11-28 | 2014-06-05 | F. Hoffmann-La Roche Ag | Novel imidazolines as dual inhibitors of mdm2 and mdmx |
| ES2707305T3 (es) | 2012-12-20 | 2019-04-03 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de HDM2 |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| EP2961735B1 (en) | 2013-02-28 | 2017-09-27 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| US9758495B2 (en) | 2013-03-14 | 2017-09-12 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| EP2970121B1 (en) * | 2013-03-15 | 2017-12-13 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| US10031416B2 (en) | 2013-08-07 | 2018-07-24 | Toyo Gosei Co., Ltd. | Reagent for enhancing generation of chemical species |
| CN104418867B (zh) * | 2013-08-26 | 2016-12-28 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途 |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| WO2015184383A1 (en) * | 2014-05-29 | 2015-12-03 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles and methods of making and using same |
| BR112017021869A2 (pt) | 2015-04-10 | 2018-12-11 | Araxes Pharma Llc | compostos quinazolina substituídos e métodos de uso dos mesmos |
| WO2016168540A1 (en) | 2015-04-15 | 2016-10-20 | Araxes Pharma Llc | Fused-tricyclic inhibitors of kras and methods of use thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| CN108779097A (zh) | 2015-11-16 | 2018-11-09 | 亚瑞克西斯制药公司 | 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法 |
| US10759808B2 (en) | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| CN113788818A (zh) | 2016-04-06 | 2021-12-14 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US10745385B2 (en) | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| EP3654968B1 (en) | 2017-07-17 | 2023-08-16 | Merck Sharp & Dohme LLC | Metallo-beta-lactamase inhibitors and methods of use thereof |
| CA3112591A1 (en) | 2018-10-08 | 2020-04-16 | The Regents Of The University Of Michigan | Small molecule mdm2 protein degraders |
| CN115776887A (zh) | 2020-03-19 | 2023-03-10 | 凯麦拉医疗公司 | Mdm2降解剂和其用途 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100486969C (zh) * | 2001-12-18 | 2009-05-13 | 霍夫曼-拉罗奇有限公司 | 顺式-2,4,5-三苯基-咪唑啉及其在肿瘤治疗中的应用 |
| CN100465163C (zh) * | 2003-06-17 | 2009-03-04 | 霍夫曼-拉罗奇有限公司 | 顺式-2,4,5-三芳基-咪唑啉类化合物 |
| US7425638B2 (en) * | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| KR100832277B1 (ko) * | 2004-05-18 | 2008-05-26 | 에프. 호프만-라 로슈 아게 | 신규 ｃｉｓ-이미다졸린 |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
-
2006
- 2006-03-13 KR KR1020077021160A patent/KR101139263B1/ko not_active IP Right Cessation
- 2006-03-13 TW TW095108346A patent/TWI314552B/zh not_active IP Right Cessation
- 2006-03-13 JP JP2008501211A patent/JP4955646B2/ja not_active Expired - Fee Related
- 2006-03-13 AU AU2006224765A patent/AU2006224765B2/en not_active Ceased
- 2006-03-13 CN CNA2006800083402A patent/CN101155784A/zh active Pending
- 2006-03-13 WO PCT/EP2006/002282 patent/WO2006097261A1/en active Application Filing
- 2006-03-13 CA CA002599476A patent/CA2599476A1/en not_active Abandoned
- 2006-03-13 BR BRPI0607445-6A patent/BRPI0607445A2/pt not_active IP Right Cessation
- 2006-03-13 EP EP06707535A patent/EP1861376A1/en not_active Ceased
- 2006-03-13 RU RU2007137987/04A patent/RU2411238C2/ru not_active IP Right Cessation
- 2006-03-13 US US11/374,407 patent/US7579368B2/en not_active Expired - Fee Related
- 2006-03-13 MX MX2007011151A patent/MX2007011151A/es active IP Right Grant
- 2006-03-13 KR KR1020107004985A patent/KR20100031783A/ko not_active Application Discontinuation
- 2006-03-14 AR ARP060100970A patent/AR053446A1/es not_active Application Discontinuation
-
2007
- 2007-08-20 IL IL185381A patent/IL185381A0/en unknown
- 2007-08-29 NO NO20074391A patent/NO20074391L/no not_active Application Discontinuation
- 2007-09-05 ZA ZA2007/07653A patent/ZA200707653B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101155784A (zh) | 2008-04-02 |
| JP2008533073A (ja) | 2008-08-21 |
| US20060211693A1 (en) | 2006-09-21 |
| AU2006224765A1 (en) | 2006-09-21 |
| RU2007137987A (ru) | 2009-04-27 |
| RU2411238C2 (ru) | 2011-02-10 |
| US7579368B2 (en) | 2009-08-25 |
| NO20074391L (no) | 2007-12-11 |
| JP4955646B2 (ja) | 2012-06-20 |
| AU2006224765B2 (en) | 2012-02-09 |
| IL185381A0 (en) | 2008-02-09 |
| WO2006097261A1 (en) | 2006-09-21 |
| TWI314552B (en) | 2009-09-11 |
| EP1861376A1 (en) | 2007-12-05 |
| KR20100031783A (ko) | 2010-03-24 |
| ZA200707653B (en) | 2013-02-27 |
| MX2007011151A (es) | 2007-10-17 |
| TW200700393A (en) | 2007-01-01 |
| KR101139263B1 (ko) | 2012-05-16 |
| CA2599476A1 (en) | 2006-09-21 |
| BRPI0607445A2 (pt) | 2009-09-01 |
| KR20070107129A (ko) | 2007-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053446A1 (es) | Compuestos cis-2,4,5-triaril-imidazolinas y su uso como medicamento anti-cancer | |
| AR049545A1 (es) | Cis-imidazolinas | |
| AR059040A1 (es) | Cis-4, 5- biaril-2- heterociclico imidazolinas como inhibidores de la mdm 2 | |
| NO20052469L (no) | Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2. | |
| CO5580803A2 (es) | Derivados de piperidin-bencensulfonamida | |
| PE20141110A1 (es) | Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| PE20020230A1 (es) | Antiinflamatorios no-esteroides | |
| AR042095A1 (es) | Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih | |
| AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
| PE20011265A1 (es) | Novedosos derivados diamino sustituidos | |
| AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa | |
| PE20070519A1 (es) | Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c | |
| AR062209A1 (es) | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| PA8607001A1 (es) | Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 | |
| AR064521A1 (es) | Activador de glucoquinasa | |
| AR054870A1 (es) | Tetrahidrobenzoxazinas como estabilizadores | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| NO20054225L (no) | Benzamid-derivater som oksytocin-agonister og vasopressin-antagonister | |
| AR078606A1 (es) | Derivados de piperidina para prevenir y/o tratar trastornos degenerativos del sistema nervioso central | |
| PE20050726A1 (es) | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos | |
| AR075534A1 (es) | Derivados de piridazinona sustituida por heteroarilo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |